THERAPY DOSSIER · th-12ddc8341217

Purple sweet potato anthocyanins

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24442992 ↗2014Reported benefit

Oral hepatoprotective ability evaluation of purple sweet potato anthocyanins on acute and chronic chemical liver injuries.

MixedChemical/toxinOralModerate and high doses (numerical values not stated in the…Before injury in the acute models; after damage was established in the chronic…

Model: Three acute chemical liver injury models (ethanol, acetaminophen, carbon tetrachloride) and one chronic carbon tetrachloride model

Moderate and high doses attenuated serum biomarker elevations and liver index in the acute models, and attenuated chronic injury on both serum biomarkers and histopathology when given after damage had formed.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…